Cargando…
Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
Cardiovascular disease (CVD) constitutes a real pandemic of the 21st century. According to data from the Centers for Disease Control and Prevention, one person dies every 34 min due to some form of CVD in the United States. Apart from the extremely high morbidity and mortality accompanying CVD, the...
Autores principales: | Dimosiari, Athina, Patoulias, Dimitrios, Kitas, George D., Dimitroulas, Theodoros |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962740/ https://www.ncbi.nlm.nih.gov/pubmed/36835838 http://dx.doi.org/10.3390/jcm12041302 |
Ejemplares similares
-
Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023) -
Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
por: Dimosiari, Athina, et al.
Publicado: (2022) -
How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed?
por: Dimosiari, Athina, et al.
Publicado: (2022) -
Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021) -
Takayasu Arteritis is Associated with Impaired Arterial Stiffness: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2022)